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Abstract
Background:  Widespread use of mammography in breast cancer screening has led to the
identification of increasing numbers of patients with ductal carcinoma in situ (DCIS). DCIS of the
breast with an area of focal invasion 1 mm or less in diameter is defined as DCIS with microinvasion,
DCIS-Mi. Identification of biological differences between DCIS and DCIS-Mi may aid in
understanding of the nature and causes of the progression of DCIS to invasiveness.
Methods: In this study, using resected breast cancer tissues, we compared pure DCIS (52 cases)
and DCIS-Mi (28 cases) with regard to pathological findings of intraductal lesions, biological factors,
apoptosis-related protein expression, and proliferative capacity through the use of
immunohistochemistry and the TdT-mediated dUTP-biotin nick end labeling (TUNEL) method.
Results: There were no differences in biological factors between DCIS and DCIS-Mi, with respect
to levels of estrogen receptor, progesterone receptor, and human epidermal growth factor
receptor type 2. The frequency of necrosis and positive expression ratio of survivin and Bax were
significantly higher in DCIS-Mi than in DCIS. In addition, apoptotic index, Ki-67 index, and positive
Bcl-2 immunolabeling tended to be higher in DCIS-Mi than in DCIS. Multivariate analysis revealed
that the presence of necrosis and positive survivin expression were independent factors associated
with invasion.
Conclusion:  Compared with DCIS, DCIS-Mi is characterized by a slightly elevated cell
proliferation capacity and enhanced apoptosis within the intraductal lesion, both of which are
thought to promote the formation of cell necrotic foci. Furthermore, the differential expression of
survivin may serve in deciding the response to therapy and may have some prognostic significance.
Published: 6 October 2008
BMC Cancer 2008, 8:287 doi:10.1186/1471-2407-8-287
Received: 17 January 2008
Accepted: 6 October 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/287
© 2008 Okumura et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:287 http://www.biomedcentral.com/1471-2407/8/287
Page 2 of 8
(page number not for citation purposes)
Background
Ductal carcinoma in situ (DCIS) is thought to be a precur-
sor of invasive ductal carcinoma (IDC) and is defined as a
lesion in which cancer cells do not grow beyond the basal
membrane of the mammary duct [1]. Since the introduc-
tion of mammography in breast cancer screening, increas-
ing numbers of DCIS are now being identified [2]. About
10 years ago, DCIS accounted for only 1–5% of all newly
diagnosed cases of breast cancer, whereas the frequency
has increased recently to 15–20% [3,4]. According to the
criteria of the American Joint Committee on Cancer
(AJCC), IDC with a microscopic focus of invasion less
than or equal to 0.1 cm in the longest dimension, is
defined as T1mic [5]. In situations where there are multi-
ple foci of microinvasion, the classification is based on the
largest focus, rather than the sum of all the individual foci
and therefore, if the size of the largest focus is less than 0.1
cm, the lesion will still be defined as T1mic [5]. This duc-
tal carcinoma in situ with microinvasion, known as DCIS-
Mi, is identified in 10–20% of cases thought to be DCIS,
through the use of preoperative diagnostic imaging and
cytology; it is considered to represent the interim stage in
the progression from DCIS to IDC [6-8]. Histopathologi-
cal factors including architectural subtypes, nuclear grade,
the presence of necrosis, tumor size, and the distance to
the surgical stump have already been reported as predic-
tors of the risk of local recurrence in DCIS [9-11]. Further
analyses of the biological parameters will make the pre-
diction of local recurrence in DCIS more accurate. At
present, various biological parameters have been reported
as prognostic factors for DCIS. Overexpression of human
epidermal growth factor receptor 2 (HER2), decreased
expression of estrogen receptor (ER), overexpression of
p53, and positive Ki-67 staining, have all been shown to
correlate with nuclear grade in both DCIS and IDC [8,12-
16]. It has also been reported that endometase/matrilysin-
2 and tissue inhibitors of metalloproteinase-2 and -4 are
overexpressed in the invasive component of DCIS [17].
However, there have been few reports investigating the
status of apoptosis and apoptosis-related factors in DCIS.
In particular, the survivin gene, shown to be expressed in
proliferating cells such as fetal and various cancer cells, is
known to be a member of the inhibitor of apoptosis pro-
tein (IAP) family, which promotes cell proliferation and
inhibits apoptosis [18-21].
Tumor progression may be induced or associated by alter-
ations in the proliferative capacity and the apoptosis
potential, and the findings may find some basic and
applied interpretations especially useful for confirming a
diagnosis, and in building up prognostic criteria. There-
fore, apoptosis-related factors (apoptotic index, survivin,
Bcl-2, Bax), cell proliferation/cycle-related factors (Ki-67,
p53, p21, cyclinD1, Rb), and other factors are analyzed in
DCIS and DCIS-Mi in this investigation.
Methods
Patients
The study population consisted of 52 patients with DCIS
and 28 with DCIS-Mi, diagnosed by postoperative his-
topathological examinations after undergoing surgery for
the diagnosis of non-invasive or invasive ductal carci-
noma of the breast at the Kumamoto University Hospital
or the Nagoya City University Hospital from 1990 to
2005. The median age was 56 years old (range, 36–86) in
patients with DCIS and 50 (range, 32–71) in patients with
DCIS-Mi. The median follow-up period was 62 months
(range, 13–140) in DCIS and 54 (range, 14–182) in
DCIS-Mi (Table 1). To date, of the DCIS-Mi patients, one
has had a recurrence in the contralateral breast and
another has developed bone metastasis. There have been
no deaths. The information was obtained from the patient
records. The ethics committee of Kumamoto University
and Nagoya City University approved the study protocol
and confirmed that it was conducted in accordance with
the guidelines of the 1975 Declaration of Helsinki.
Informed consent was obtained from all patients before
or after surgery. Histological diagnosis was made by 2 spe-
cialized pathologists. The histological subtypes were
determined on the predominant area occupying most of
the lesion, although in some cases multiple histological
subtypes were mixed. When there were multiple foci of
microinvasion, if the size of the largest focus was less than
0.1 cm, the lesion was regarded as DCIS-Mi.
Histological variables, including classification of histolog-
ical subtypes, grade of nuclear atypia, and the presence of
necrotic foci, were evaluated on slides stained with hema-
toxylin-eosin (HE). According to the Van Nuys classifica-
tion [22], cases were classified into three groups: high-
nuclear grade (Grade 3); non-high nuclear grade with
necrosis (Grade 2); and non-high nuclear grade without
necrosis (Grade 1). In some cases, microinvasion was con-
firmed by staining the basal membrane with type IV colla-
genase [23].
Immunohistochemistry
Resected specimens were fixed in 10% buffered-formalin
and embedded in paraffin within 24–48 hours. Four-μm
sections were cut from this paraffin block and mounted
on adhesive-coated slides (Aminosilane-coated slides;
MATSUNAMI GLASS Co. Ltd., Japan) for immunohisto-
chemistry [15]. The sections were deparaffinized in xylene
(5 × 5 minutes) and ethanol (2 × 100%, 1 × 90%, 1 ×
80%, 1 × 70%). Subsequently, antigen retrieval was per-
formed in citrate buffer at pH 9 for survivin as previously
described [24], using a microwave oven (after boiling, 3 ×
10 minutes at 750W or 4 × 15 minutes at 170W). After
leaving at room temperature for 20 minutes, sections were
immersed in phosphate-buffered saline (PBS). Endog-
enous peroxidase was blocked by incubation with 3%BMC Cancer 2008, 8:287 http://www.biomedcentral.com/1471-2407/8/287
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H2O2 in methanol for 10 minutes. Sections were washed
with PBS (3 × 5 minutes) followed by blocking with 5%
skimmed milk for 20 minutes [25].
Immunohistochemical staining was performed by the avi-
din-biotin complex (ABC) method using the Vectastain
ABC kit for ER, progesterone receptor (PgR), HER2, Ki-67,
survivin, p53, p21, cyclin D1, and Rb, (monoclonal anti-
bodies, DAKO, Netherlands) and by the immuno-enzyme
polymer method (indirect method, EnVision system,
DAKO, Netherlands) using Histofine Simple Stain MAX
PO (Nichirei Bioscience, Tokyo Japan) for Bcl-2 and Bax
[26]. Sections were incubated with dilutions of primary
antibodies for 60 minutes at room temperature. After
washing with PBS (3 × 5 minutes), sections were incu-
bated with biotinylated secondary antibodies for 30 min-
utes. Following this, the sections were washed again with
PBS (3 × 5 minutes) and then reacted with an ABC solu-
tion for 30 minutes at room temperature. After a further
washing with PBS (3 × 5 minutes), the sections were
stained with 3, 3'-diaminobenzidine (DAB) substrate
solution.
In the immuno-enzyme polymer (indirect) method, sec-
tions were incubated with dilutions of primary antibodies
at 4°C overnight. After washing with PBS (3 × 5 minutes),
sections were reacted with the Histofine Simple Stain
MAX PO (mouse or rabbit), washed again with PBS (3 × 5
minutes), and then stained with DAB solution [25].
Nuclear staining of all sections was done with hematoxy-
lin. The sections were mounted after dehydration (1 ×
70%, 1 × 80%, 1 × 90%, 2 × 100% ethanol) and penetra-
tion (3 × xylene for 3 minutes). Details of the primary
antibodies used in this study are shown in Table 2.
Evaluation of immunohistochemistry
For Ki-67 expression, the percentage of cancer cells with
positively-stained nuclei was determined. Nuclear labe-
ling of more than 10% of all observed cancer cells was
regarded as positive for ER, PgR, p53, p21, cyclin D1, and
Rb [25]. HER2 expression was categorized into no stain-
ing (0), weak staining (+1), moderate staining (+2), or
strong staining (+3), and was regarded as positive only
when cancer cells showed strong staining (+3) [15]. Stain-
ing of more than 5% of all observed cancer cells was
regarded as positive for survivin, Bcl-2, and Bax [20,27].
Apoptosis
Apoptosis was detected by the TdT-mediated dUTP-biotin
nick end labeling (TUNEL) method using ApopTag Perox-
idase In Situ Apoptosis Detection Kit (S7100; Chemicon
International, CA, USA) [28]. After deparaffinization, sec-
tions were incubated with Proteinase K for 15 minutes at
room temperature and immersed in pure water. After this,
the sections were incubated with 3% H2O2 for 5 minutes
at room temperature followed by washing with PBS (2 ×
5 minutes). Sections were incubated with equilibration
buffer for at least 10 minutes at room temperature and
then with working strength TdT enzyme at 37°C for 60
minutes, at which point the sections were incubated with
Table 1: Histological characteristics of intraductal component in ductal carcinoma in situ (DCIS) and in ductal carcinoma in situ with 
microinvasion (DCIS-Mi)
DCIS DCIS-Mi
Number of patients 52 28
Median follow-up period, months (range) 62 (3–140) 54 (14–182)
Median age, years (range) 56 (36–86) 50 (32–71)
Architectural classification
comedo 8 (15.4%) 10(35.7%) P = 0.073
Papillary 21 (40.4%) 10 (35.7%) (comedo vs others)
cribriform 15 (28.8%) 4 (14.3%)
solid 4 (7.7%) 4 (14.3%)
low papillary 4 (7.7%) 0 (0)
Nuclear Grade
Grade 1 21 (40.4%) 7 (25) P = 0.16
Grade 2 29 (55.8%) 18 (64.3) (1 vs. 2,3)
Grade 3 2 (3.9%) 3 (10.7)
Necrosis
absent 25 (48.1%) 4 (14.3%) P = 0.0017
Present 27 (51.9%) 24 (85.7%)
Van Nuys Classification*
Grade 1 25 (48.1%) 4 (14.3%) P = 0.0017
Grade 2 25 (48.1%) 21 (75%) (1 vs. 2,3)
Grade 3 2 (3.9%) 3 (10.7%)
* Van Nuys Classification: Grade 1 = non-high nuclear grade without necrosis; Grade 2 = non-high nuclear grade with necrosis; Grade 3 = high-
nuclear grade.BMC Cancer 2008, 8:287 http://www.biomedcentral.com/1471-2407/8/287
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working strength stop/wash buffer for 10 minutes after
being agitated for 15 seconds at room temperature, fol-
lowed by washing with PBS (2 × 1 minute). Sections were
then incubated with anti-digoxigenin conjugate for 30
minutes at room temperature followed by washing with
PBS (4 × 2 minutes). Sections were stained with DAB solu-
tion, dehydrated, and mounted. To quantitate apoptosis,
the mean number of positive nuclei per 1000 counted
nuclei/field was determined in three fields within the can-
cerous areas of the intraductal components. The mean
number of positive nuclei was defined as the apoptotic
index.
Statistical methods
The statistical tests were utilized to examine the difference
in each factor between DCIS and DCIS-Mi. Quantitative
analyses (Ki-67 and apoptotic index) were performed
using the Mann-Whitney U test; all other factors were ana-
lyzed with the Chi-squared test and Fisher's exact test. For
all comparisons, differences were considered significant
when the P-value was less than 0.05. Statistical analyses
were performed using the statistical software JMP Japa-
nese Version 4.0 (SAS).
Results
Histological evaluation
Results showed that the comedo type tended to be found
more frequently in DCIS-Mi (36%) than in DCIS (18%),
although this difference did not reach statistical signifi-
cance (P  = 0.073). There was no difference in nuclear
grade between the two groups but a necrotic focus was
found at a significantly higher frequency in DCIS-Mi
(85.7%) than in DCIS (51.9%) (P = 0.0017). According to
the Van Nuys classification, which evaluates both nuclear
grade and necrosis, the grade of malignancy was signifi-
cantly higher in DCIS-Mi (14.3%, Grade 1) than in DCIS
(48.1%, Grade 1) (P = 0.0017, Grade 1 vs. Grade 2 and 3)
(Table 2).
Relative expression of hormone receptors, HER2, and Ki-
67: DCIS vs. DCIS-Mi
There was no significant difference between DCIS and
DCIS-Mi in expression levels of universal biological fac-
tors such as ER, PgR, and HER2. The Ki-67 index tended to
be higher in DCIS-Mi (22.8 ± 2.0%) than in DCIS (17.9 ±
1.5%), although the difference was not statistically signif-
icant (P = 0.052) (Table 3). Representative microscopic
views of immunohistochemical detection were shown in
Fig. 1.
Relative expression of apoptosis-related markers: DCIS vs. 
DCIS-Mi
The relative expressions of the apoptosis-related markers
in DCIS and DCIS-Mi are shown in Table 4. Apoptotic
index tended to be higher in DCIS-Mi (0.29 ± 0.06%)
Table 2: Details of immunohistochemistry and the antibodies
Antibody Source Clone Dilution Pretreatment Citrate buffer Incubation Detection system
ER DAKO 1D5 1/50 4 × 15 min MW pH6 1 h RT ABC
PgR DAKO 636 1/800 4 × 15 min MW pH6 1 h RT ABC
HER2 DAKO 1/300 4 × 15 min MW pH6 1 h RT ABC
Ki-67 DAKO MIB-1 1/50 3 × 10 min MW pH9 1 h RT ABC
Bcl-2 DAKO 124 1/50 3 × 10 min MW pH9 ON 4°C En-Vision
Bax DAKO 1/50 3 × 10 min MW pH6 ON 4°C En-Vision
Survivin SantaC D-8 1/50 3 × 10 min MW pH9 1 h RT ABC
p53 DAKO DO-7 1/50 3 × 10 min MW pH9 1 h RT ABC
p21 DAKO SX118 1/25 3 × 10 min MW pH9 1 h RT ABC
cyclinD1 NovoC P2D11F11 1/50 3 × 10 min MW pH9 1 h RT ABC
Rb NovoC 13A10 1/100 3 × 10 min MW pH6 1 h RT ABC
ER = estrogen receptor; PgR = progesterone receptor; MW = microwave; RT = room temperature; ON = overnight; Santa C = Santa Cruz; 
NovoC = NovoCastra.
Table 3: Hormone Receptor status, HER2 status and Ki-67 index 
in DCIS and DCIS-Mi
DCIS DCIS-Mi P-value
Estrogen Receptor
positive 38 (73.1%) 19 (67.9%) 0.62
negative 14 (26.9%) 9 (32.1%)
Progesterone Receptor
positive 37 (71.2%) 16 (57.1%) 0.21
Negative 15 (28.9%) 12 (42.9%)
c-erbB-2
0, 1+,2+ 43 (82.7%) 22 (78.6%) 0.65
3+ 9 (17.3%) 6 (21.4%)
Ki-67 index
positive rate % 17.9 ± 1.5 22.8 ± 2.0 0.052
mean ± SD
DCIS = ductal carcinoma in situ; DCIS-Mi = ductal carcinoma in situ 
with microinvasion; SD = standard deviation.BMC Cancer 2008, 8:287 http://www.biomedcentral.com/1471-2407/8/287
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than in DCIS (0.17 ± 0.04%) (P = 0.082). The expression
of Bax, a promoting factor of apoptosis, was significantly
higher in DCIS-Mi (96.4%) than in DCIS (71.2%) (P =
0.0028). The expression of survivin, an inhibiting factor
of apoptosis, was also significantly higher in DCIS-Mi
(85.7%) than in DCIS (55.8%) (P = 0.0048), while the
expression of another apoptosis inhibitor (Bcl-2) tended
to be found more frequently in DCIS-Mi (78.6%) than in
DCIS (58.8%), although this did not reach statistical sig-
nificance (P  = 0.071). There was no difference in the
expression levels of p53, p21, cyclin D1, and Rb between
DCIS and DCIS-Mi (Table 4). Because no cases were
detected showing nuclear staining of survivin, in this
study cases were regarded positive only when cytoplasmic
staining was detectable. Based on this limitation the sur-
vivin expression showed a positive correlation with Bax
expression (P  = 0.038) and cases positive for survivin
tended to show a higher apoptotic index (P  = 0.077)
(Table 5).
Univariate and multivariate analyses for factors affecting 
invasion
Univariate analysis for factors affecting invasion beyond
the mammary ducts identified the presence of necrosis,
positive Bax expression, and positive survivin expression
to be significant factors and revealed apoptotic index, pos-
itive Bcl-2 expression, and Ki-67 positivity to have a weak
correlation with invasion. Multivariate analysis revealed
that the presence of necrosis (P = 0.017, odds ratio 5.19,
95% Confidence Interval; CI 1.47–22.7), and positive sur-
vivin expression (P = 0.044, odds ratio 3.98 95%CI 1.11–
17.2) were independent factors associated with invasion
(Table 6).
Representative microscopic views ofimmunohistochemical detection Figure 1
Representative microscopic views of immunohistochemical detection. Intraductal component found in patients with 
DCIS, using A. hematoxylin-eosin (HE) staining, the frames show cells stained for B. estrogen receptor (ER), C. HER2, D. Ki-
67, E. p21, F. BCL-2, G. BAX, and H. Survivin 1, respectively.  I. Survivin 2 shows moderately positive Survivin staining 
detected in another patient with DCIS. (original magnification × 200)
A A B B C C
D D E E F F
G G H H I IBMC Cancer 2008, 8:287 http://www.biomedcentral.com/1471-2407/8/287
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Discussion
The investigation of the biological factors of DCIS-Mi may
yield some explanations to the progression from DCIS to
IDC. In this study, we examined the intraductal compo-
nents of both DCIS and DCIS-Mi for expression of these
factors, but not the invasive components. The reasons for
this were: the purpose of this study was to determine the
difference between the intraductal components of DCIS
and DCIS-Mi; it was difficult to evaluate invasive foci
because of their small size; in some cases, invasive foci
were undetectable on slides for immunohistochemical
staining; in histological diagnosis, it was important to
evaluate the most predominant area of each section.
Results from the present analysis showed that the fre-
quency of necrosis was significantly higher in DCIS-Mi
compared with DCIS.
The important result obtained from our analysis of apop-
tosis-related factors was that the positive rate of survivin
expression was significantly higher in DCIS-Mi than in
DCIS (P  = 0.0048). The survivin  gene, shown to be
expressed in proliferating cells such as fetal and various
cancer cells, is known to be a member of the IAP family
which promotes cell proliferation and inhibits apoptosis.
In particular, because survivin is expressed specifically in
cancer cells and proliferating cells, this gene is likely to be
involved in cell proliferation and/or differentiation
[29,30].
Previous reports have shown that, in invasive ductal carci-
noma of the breast, survivin expression is significantly
higher in the invasive foci than in the intraductal compo-
nents and that high nuclear expression of survivin in the
invasive foci is associated with a higher risk of recurrence
and mortality [19,30]. However, there have also been
reports that showed no correlation between survivin
expression and prognosis in patients with breast cancer
[27,31], suggesting that its prognostic value is controver-
sial. With the antibody used in this present study, sur-
vivin-specific staining in the nucleus was barely
detectable, and therefore we relied upon cytoplasmic
staining for the evaluation of survivin expression. Reasons
for the lack of nuclear expression in this study remain
unclear and must be sought in further study on survivin
splice variants.
There have been many studies reporting that Bcl-2, an
apoptosis inhibitor, shows a positive correlation with hor-
mone receptors in breast cancer tissues and is a favorable
prognostic factor [26]. In addition, it has been reported
that the expression of an apoptosis promoter Bax is asso-
ciated with the degree of local recurrence in DCIS [32].
Furthermore, the relation between Bcl-2 and Bax is under
debate with some reports showing a direct correlation
between them and others showing no such correlation
[33].
In our present results, the Bax expression was significantly
higher (P = 0.0028) and the Bcl-2 expression tended to be
slightly higher (P = 0.071) in DCIS-Mi compared with
DCIS. These results show a positive correlation between
Bax and Bcl-2 and their increased expression with the pro-
gression from DCIS to DCIS-Mi. Thus, this may suggest
that the specific interaction between Bax and Bcl-2 is
involved in apoptosis during this progression.
In our present study, we also found a tendency for higher
apoptotic and Ki-67 indices in DCIS-Mi relative to DCIS.
It is well known that these indices are higher in invasive
ductal carcinoma of the breast than in fibroadenoma, a
benign breast tumor. In DCIS, it has been shown that pro-
liferation and apoptosis markers are higher in poorly-dif-
ferentiated tumors than in well-differentiated tumors,
which has led some investigators to believe that the differ-
Table 4: Apoptosis-related factors in DCIS and DCIS-Mi
DCIS DCIS-Mi P-value
Apoptotic Index (N/1000) 1.7 ± 0.4 2.9 ± 0.6 0.082
Bcl-2
negative 21 (41.2%) 6 (21.4%) 0.071
Positive 30 (58.8%) 22 (78.6%)
Bax
negative 15 (28.8%) 1 (3.6%) 0.0028
Positive 37 (71.2%) 27 (96.4%)
Survivin
negative 23 (44.2%) 4 (14.3%) 0.0048
positive 29 (55.8%) 24 (85.7%)
p53
positive 39 (76.5%) 23 (82.1%) 0.55
Negative 12 (23.5%) 5 (17.9%)
p21
positive 36 (69.2%) 15 (53.6%) 0.17
negative 16 (30.8%) 13 (46.4%)
cyclinD1
positive 36 (70.6%) 18 (64.3%) 0.57
Negative 15 (29.4%) 10 (35.7%)
Rb
positive 35 (68.6%) 23 (82.1%) 0.18
negative 16 (31.4%) 5 (17.9%)
DCIS = ductal carcinoma in situ; DCIS-Mi = ductal carcinoma in situ 
with microinvasion.
Table 5: Relationship among apoptosis-related factors
Apoptosis index Survivin Bax
Bcl-2 0.11 0.65 0.042
Bax 0.018 0.038 -
Survivin 0.077 - -BMC Cancer 2008, 8:287 http://www.biomedcentral.com/1471-2407/8/287
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ence between DCIS and invasive carcinoma is a relative
decrease in apoptosis [26]. Taken together, it has been
suggested that both cell proliferation and apoptosis are
enhanced in DCIS-Mi as compared to DCIS.
Furthermore, multivariate analysis for apoptosis-related
factors affecting invasion, identified the presence of necro-
sis (P = 0.017) and high survivin expression (P = 0.044) as
statistically significant factors. We also demonstrated that
the frequency of apoptosis (P = 0.077) and nuclear grade
(P = 0.081) tended to be higher in cases with positive
immunolabeling for survivin, suggesting that survivin
could be a marker reflecting the biological characteristics
of DCIS and DCIS-Mi. In addition, there was a positive
correlation between the expression of the anti-apoptotic
factor survivin and that of an apoptosis promoter Bax (P =
0.038). These findings suggest that a balance is main-
tained in DCIS-Mi between survivin and Bax.
These results revealed that, compared to DCIS, DCIS-Mi is
histologically associated with necrotic focus more com-
monly, and with a significantly higher expression of apop-
tosis-related factors, including survivin and Bax. In other
words, DCIS-Mi is characterized by a slightly elevated cell
proliferation ability and a tendency for enhanced apopto-
sis, which could increase cell death and subsequently pro-
mote the formation of necrotic foci [34]. In clinical
settings, survivin may prove to be a useful marker to indi-
cate a difference in biological features between DCIS and
DCIS-Mi, and it could become one of the parameters used
to determine whether adjuvant systemic therapy or surviv-
ing-inhibiting therapy should be given to patients with
DCIS.
Conclusion
Compared with DCIS, DCIS-Mi is characterized by a
slightly elevated cell proliferation capacity and enhanced
apoptosis within the intraductal lesion, which are thought
to promote the formation of cell necrotic foci. Further-
more, survivin is one of the markers indicating the differ-
ence in biological features between DCIS and DCIS-Mi,
and further investigation of this marker is required to
determine if this difference in expression could serve as an
indicator for identifying which patients would benefit
from adjuvant systemic therapy.
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